Eliem Therapeutics (UK) Ltd. Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2019)

Organization Overview

First Clinical Trial
2020
NCT04688671
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Eliem Therapeutics (UK) Ltd.

Active Ingredients

Drugs in Phase 2 Trials (1)

etx-018810 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Neuropathies (Phase 2)

Neuralgia (Phase 2)

Peripheral Nervous System Diseases (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1